Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Janux Therapeutics, Inc. (JANX) had Return on Equity of -3.34% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-31.95M |
|
-- |
|
-- |
|
$42.40M |
|
$-42.40M |
|
$10.46M |
|
$-31.95M |
|
$-31.95M |
|
$-31.95M |
|
$-31.95M |
|
$-31.95M |
|
$-31.95M |
|
$-42.40M |
|
$-45.46M |
|
61.97M |
|
61.97M |
|
$-0.51 |
|
$-0.51 |
|
| Balance Sheet Financials | |
$975.89M |
|
$3.85M |
|
$25.68M |
|
$1.00B |
|
$25.00M |
|
-- |
|
$19.75M |
|
$44.74M |
|
$956.82M |
|
$956.82M |
|
$956.82M |
|
60.38M |
|
| Cash Flow Statement Financials | |
$-82.23M |
|
$-300.98M |
|
$4.95M |
|
$431.42M |
|
$53.15M |
|
$-378.27M |
|
$40.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
39.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-83.28M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-3.34% |
-3.34% |
|
-3.19% |
|
-3.34% |
|
$15.85 |
|
$-1.34 |
|
$-1.33 |
|